Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered in the fourth quarter. The product's sales fell 62% year over year to $198 ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...

For example, after respiratory ... [+] syncytial virus (RSV) cases jumped in December 2024, the New York City Health Department suggested that people mask up in crowded indoor places. (Photo by ...

Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. Get two weeks of ...

Likewise, Abrysvo, a vaccine against RSV, which will generate revenues of ~$750m in 2024 — up 44%. Another major revenues contributor to Pfizer's revenues — the blood-thinner Eliquis ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Recently, Pfizer found itself in the agency's crosshairs thanks to one of its M&A plays. Now, Pfizer—which purchased neuroscience specialist Biohaven for $11.6 billion in 2022—is committing ...